[Pubmed] Costs and Utilization of New-to-Market Neurologic Medications
Posté : 30 nov. 2022 12:00
Neurology. 2022 Nov 30:10.1212/WNL.0000000000201627. doi: 10.1212/WNL.0000000000201627. Online ahead of print.
ABSTRACT
BACKGROUND AND OBJECTIVES: To compare the utilization and costs (total and out-of-pocket) of new-to-market neurologic medications with existing guideline-supported neurologic medications over time.
METHODS: We used a healthcare pharmaceutical claims database (from 2001-2019) to identify patients with both a diagnosis of one of 11 separate neurologic conditions and either a new-to-market medication or an existing guideline-supported medication for that condition. Neurologic conditions included orthostatic hypotension, spinal muscular atrophy, Duchenne's disease, Parkinson's disease, Multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, Huntington's disease, tardive dyskinesia, transthyretin amyloidosis, and migraine. New-to-market medications were defined as all neurologic medications approved by the FDA between 2014 and 2018. In each year, we determined the median out-of-pocket and standardized total cost for a 30-day supply of each medication. We also measured the proportion of patients receiving new-to-market medications compared with all medications specific for the relevant condition.
RESULTS: We found that the utilization of most new-to-market medications was small (
Source: https://pubmed.ncbi.nlm.nih.gov/3645060 ... 3&v=2.17.8